ID   BID007
AC   CVCL_W890
SY   Beth Israel Deaconess 007
DR   cancercelllines; CVCL_W890
DR   Cosmic; 2093906
DR   Wikidata; Q54796550
RX   PubMed=24353160;
RX   PubMed=31467113;
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Ala763_Tyr764insPheGlnGluAla (c.2284-5_2290dup); ClinVar=VCV000045248; Zygosity=Unspecified (PubMed=24353160).
CC   Omics: Variations; CNV analysis.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
CA   Cancer cell line
DT   Created: 17-07-14; Last updated: 10-04-25; Version: 11
//
RX   PubMed=24353160; DOI=10.1126/scitranslmed.3007205; PMCID=PMC3954775;
RA   Yasuda H., Park E., Yun C.-H., Sng N.J., Lucena-Araujo A.R.,
RA   Yeo W.-L., Huberman M.S., Cohen D.W., Nakayama S., Ishioka K.,
RA   Yamaguchi N., Hanna M., Oxnard G.R., Lathan C.S., Moran T.,
RA   Sequist L.V., Chaft J.E., Riely G.J., Arcila M.E., Soo R.A.,
RA   Meyerson M.L., Eck M.J., Kobayashi S.S., Costa D.B.;
RT   "Structural, biochemical, and clinical characterization of epidermal
RT   growth factor receptor (EGFR) exon 20 insertion mutations in lung
RT   cancer.";
RL   Sci. Transl. Med. 5:216ra177.1-216ra177.10(2013).
//
RX   PubMed=31467113; DOI=10.1158/1541-7786.MCR-19-0419; PMCID=PMC6872223;
RA   Udagawa H., Hasako S., Ohashi A., Fujioka R., Hakozaki Y., Shibuya M.,
RA   Abe N., Komori T., Haruma T., Terasaka M., Fujita R., Hashimoto A.,
RA   Funabashi K., Yasuda H., Miyadera K., Goto K., Costa D.B.,
RA   Kobayashi S.S.;
RT   "TAS6417/CLN-081 is a pan-mutation-selective EGFR tyrosine kinase
RT   inhibitor with a broad spectrum of preclinical activity against
RT   clinically relevant EGFR mutations.";
RL   Mol. Cancer Res. 17:2233-2243(2019).
//